Authors
Yadi Zhou, Yuan Hou, Muzna Hussain, Sherry‐Ann Brown, Thomas Budd, WH Wilson Tang, Jame Abraham, Bo Xu, Chirag Shah, Rohit Moudgil, Zoran Popovic, Leslie Cho, Mohamed Kanj, Chris Watson, Brian Griffin, Mina K Chung, Samir Kapadia, Lars Svensson, Patrick Collier, Feixiong Cheng
Publication date
2020/12/1
Journal
Journal of the American Heart Association
Volume
9
Issue
23
Pages
e019628
Description
Background
The growing awareness of cardiovascular toxicity from cancer therapies has led to the emerging field of cardio‐oncology, which centers on preventing, detecting, and treating patients with cardiac dysfunction before, during, or after cancer treatment. Early detection and prevention of cancer therapy–related cardiac dysfunction (CTRCD) play important roles in precision cardio‐oncology.
Methods and Results
This retrospective study included 4309 cancer patients between 1997 and 2018 whose laboratory tests and cardiovascular echocardiographic variables were collected from the Cleveland Clinic institutional electronic medical record database (Epic Systems). Among these patients, 1560 (36%) were diagnosed with at least 1 type of CTRCD, and 838 (19%) developed CTRCD after cancer therapy (de novo). We posited that machine learning algorithms can be implemented to predict CTRCDs in …
Total citations
Scholar articles
Y Zhou, Y Hou, M Hussain, SA Brown, T Budd… - Journal of the American Heart Association, 2020